BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...

BridgeBio Pharma Inc. (BBIO) announced that the U.S. Food and Drug Administration approved Attruby or acoramidis, an ...

Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer ...

The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart ...

The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...

The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...

The latest health news highlights BridgeBio's new heart drug approved by the FDA, novel findings in breast cell research, ...

Experts view BridgeBio’s acoramidis—which has an FDA action date of Nov. 29—as either similar to or incrementally better than ...

The latest health news highlights FDA's approval of BridgeBio's drug for a rare heart condition, cancer features in healthy ...

BridgeBio Pharma Inc. gained US approval for a drug to treat a progressive and deadly form of heart disease, paving the way ...

I have switched from rental properties to REITs for most of my investments. Read here for an analysis of pros and cons of my ...

Alphabet X spinoff Wing on Wednesday confirmed that it has started delivering blood samples via drone. The program, announced ...